Olympus has introduced its new endoscopic ultrasound processor, known as EVIS EUS Endoscopic Ultrasound Centre Olympus EU-ME3.

The new ultrasound processor has been designed to address the needs of healthcare professionals for high-quality clear images during endoscopic ultrasound procedures.

It can be used for endoscopic ultrasonography (EUS) imaging to help diagnose lesions in the pancreas and bile ducts.

The technology also helps with the locating of lesions deep inside the body, which are invisible to gastrointestinal endoscopes.

Furthermore, it improves the detailed examination of pancreatic cancer and pancreatitis, as well as the diagnosis of cancer invasion in the oesophagus or stomach.

Olympus stated that the new EU-ME3 also facilitates the visuals of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), which helps in early, minimally invasive diagnosis and lung cancer staging.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Olympus Endoscopic Solutions Division head Hironobu Kawano said: “It is said that pancreatic cancer is difficult to be detected in its early stages, and that lung cancer has the highest mortality rate among all cancers.

“With the launch of the EU-ME3, Olympus aims to enhance the standard of care including these diseases and to further improve the quality of life of patients.”

Customised to improve various procedures, the EU-ME3 offers enhanced image quality and functionality compared to the previous generation model, EU-ME2.

It also provides improved visualisation for more reliable diagnosis and treatment.

EU-ME3 includes a shear wave quantification feature that provides quantitative information regarding the stiffness of tumours and inflamed lesions to enable accurate diagnosis.

This information is crucial for diagnosing the degree of pancreatitis and malignancy of pancreatic cancer during endoscopic ultrasonography.

Along with a basic observation mode, the EU-ME3 provides several software options for individual clinical requirements.

It also has smart and customisable user settings to address the needs of multiple specialities as well as personal requirements.

Olympus intends to launch the new endoscopic ultrasound processor in Europe, the Middle East, Africa, parts of Asia and Oceania within this fiscal year.